Company Analysis
Sign in

Immutep Limited (IMMP)

Nasdaq: IMMP · Pharmaceutical Preparations · Sydney,, AU · filing with the SEC since 2012
Full chart Alerts Compare
Grade5.7
◀ Past 5.7● Present 5.5▶ Future 5.9
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Immutep Limited

Nine metrics read from its own filings, by tense
Headline grade
5.7/10
◀ Past5.725% of the headline
● Present5.535% of the headline
▶ Future5.940% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.7/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Immutep Limited's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
5.0/10

What has it actually done, year after year?

+19.8% a year over 10 filed years; profitable in 0 of 9.

weight 45% of this tense · 50th percentile among 323 sector filers · read for its customers

From the record

Immutep Limited's 10 filed years say what it did: revenue went from AUD 2 million in fiscal 2016 to AUD 10 million in fiscal 2025, up 19.8% a year; it rose in 7 of 9 years; the deepest fall was 76% from fiscal 2020 to fiscal 2021; net income was positive in 0 of 9 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span19.8%top 40% of its family
  • the share of years revenue rosetop 28% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak76.0%bottom 41% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
5.0/10

How has it treated the people who own it?

SI estimate 5.0/10, confidence 35 of 100 (one part).

weight 33% of this tense · 50th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 50% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Immutep Limited's shareholder treatment is put at 5.0 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 50% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.5/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
6.4/10

Is it financially healthy right now?

ROE -43%: lost 43¢ per shareholder dollar. Leverage 9%: owes 9¢ per asset dollar.

weight 45% of this tense · 64th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-06-30, Immutep Limited lost about 43 cents for every dollar of shareholders' money. Leverage: it owed about 9 cents per dollar of assets, and net share issuance: its share count grew 21.2% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 14% of its family
  • return on equitytop 44% of its family
  • the share count against the year beforebottom 49% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
4.6/10

How strong is its position in its industry?

bottom 46% of 315 in its family; net margin -594.6%.

weight 22% of this tense · 46th percentile among 315 sector filers · read for its customers

From the record

Immutep Limited's standing among 315 graded names in its industry family: revenue of AUD 10 million in fiscal 2025 is not ranked by size, since the family reports in another currency; a net margin of -594.6% ranks in the bottom 35%; revenue growth of 15.2% a year over the last 3 filed years ranks in the top 42% (its annual reports).

What it rests on

  • net margin-594.6%bottom 35% of its family
  • three-year revenue growth15.2%top 42% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-04-01 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-04-01 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned
family median, 371 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Immutep Limited's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-04-01 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.9/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed
5.6/10

How much room does it have to grow?

top 44% of 273 in its family for room to expand.

weight 33% of this tense · 56th percentile among 273 sector filers · read for itself

From the record

Immutep Limited's room to grow, from the newest filed statements (fiscal 2025): cash of AUD 67 million against no long-term debt tagged leaves 42.9% of its assets as net cash, top 36% of its family; cash from operations less capital spending is -601% of revenue (bottom 32%); research spending of 481.8% of revenue (top 28%) (its annual report).

What it rests on

  • cash less debt against assets42.9%top 36% of its family
  • cash from operations less capital spending against revenue-601.0%bottom 32% of its family
  • research spending against revenue481.8%top 28% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
6.8/10

What could actually drive growth from here?

top 32% of 306 in its family for growth drivers.

weight 45% of this tense · 68th percentile among 306 sector filers · read for its customers

From the record

Immutep Limited's growth drivers, from the filed years to fiscal 2025: revenue grew 15.2% a year over the last three filed years against 19.8% over all 10, slowing (bottom 43% of its family); the newest year grew 31.8% (top 32%); research spending grew 25.2% a year (top 18%); capital spending grew 25.9% a year (top 23%) (its annual reports). Immutep Limited tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span-4.6 points a yearbottom 43% of its family
  • the newest year's revenue growth31.8%top 32% of its family
  • three-year growth of research spending25.2%top 18% of its family
  • three-year growth of capital spending25.9%top 23% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
4.5/10

Did its newest year beat what its own record pointed to?

bottom 44% of 233 in its family for expectations against reality.

weight 22% of this tense · 44th percentile among 233 sector filers · read for its shareholders

From the record

Immutep Limited's newest year against its own record: revenue of AUD 10 million in fiscal 2025 came in 22.4% above the AUD 8 million its prior three years' pace pointed to (top 27% of its family); net income of AUD 61 million against a prior three-year average of AUD 38 million (bottom 22%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 38%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace22.4%top 27% of its family
  • net income against the prior three years' average-61%bottom 22% of its family
  • net margin against its prior average+1.6 pointsbottom 38% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton IMMP · research, not advice